Mary Polan Net Worth

The estimated Net Worth of Mary Lake Ph D Polan is at least $13 Миллион dollars as of 18 May 2022. Mary Polan owns over 1,624 units of QuidelOrtho stock worth over $926,287 and over the last 21 years he sold QDEL stock worth over $11,876,856. In addition, he makes $184,917 as Independent Director at QuidelOrtho.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mary Polan QDEL stock SEC Form 4 insiders trading

Mary has made over 41 trades of the QuidelOrtho stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 1,624 units of QDEL stock worth $72,836 on 18 May 2022.

The largest trade he's ever made was exercising 27,188 units of QuidelOrtho stock on 23 October 2020 worth over $588,076. On average, Mary trades about 3,226 units every 48 days since 2003. As of 18 May 2022 he still owns at least 20,653 units of QuidelOrtho stock.

You can see the complete history of Mary Polan stock trades at the bottom of the page.

Mary Polan biography

Dr. Mary Lake Polan serves as Independent Director of Quidel Corporation. Dr. Polan was an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine from 2007 to 2014 and then in 2015 rejoined the Department of Obstetrics and Gynecology at Yale University School of Medicine as Clinical Professor. She was a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine where she served from 1990 to 2005. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her Master in Public Health from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan was on the faculty at Yale University until 1990, when she joined Stanford University. Dr. Polan is a practicing clinical Reproductive Endocrinologist with a research interest in ovarian function and granulosa cell steroidogenesis. More recently, Dr. Polan’s interests have been in the interaction between the immune and endocrine systems: the role of monokines in reproductive events and gene expression in stress urinary incontinence as well as brain activation in human sexual function. Dr. Polan is also currently a director of Chembio Diagnostic Systems, Inc., a diagnostics company, NX Prenatal Inc, a private molecular diagnostics company and Or-Genix Therapeutics, Inc., a private, development-stage specialty women’s health and dermatology company.

What is the salary of Mary Polan?

As the Independent Director of QuidelOrtho, the total compensation of Mary Polan at QuidelOrtho is $184,917. There are 17 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of $4,168,770.

How old is Mary Polan?

Mary Polan is 76, he's been the Independent Director of QuidelOrtho since 1993. There are no older and 28 younger executives at QuidelOrtho.

Insiders trading at QuidelOrtho

Over the last 21 years, insiders at QuidelOrtho have traded over $509,235,797 worth of QuidelOrtho stock and bought 304,015 units worth $10,385,234 . The most active insiders traders include Jack W Schuler, Matthew Strobeck и Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of $1,246,606. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth $3,078,785.

What does QuidelOrtho do?

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

Complete history of Mary Polan stock trades at Chembio Diagnostics и QuidelOrtho

QuidelOrtho executives and stock owners

QuidelOrtho executives and other stock owners filed with the SEC include:

• Douglas Bryant,
  President, Chief Executive Officer, Director
• Douglas C. Bryant,
  Pres, CEO & Director
• Randall Steward,
  Chief Financial Officer
• Michael Abney,
  Senior Vice President - Distribution
• Robert Bujarski,
  Chief Operating Officer
• Ratan Borkar,
  Senior Vice President - International Commercial Operations
• Werner Kroll,
  Senior Vice President - R&D
• Edward Russell,
  Senior Vice President - Business Development
• Robert J. Bujarski,
  Chief Operating Officer
• Randall J. Steward,
  Chief Financial Officer
• Dr. Werner Kroll,
  Sr. VP of R&D
• Ratan S. Borkar,
  Sr. VP of International Commercial Operations
• Robert J. Bujarski J.D.,
  Pres & COO
• Kenneth Buechler,
  Independent Chairman of the Board
• Edward Michael,
  Independent Director
• Ken Widder,
  Independent Director
• Charles Slacik,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Mary Polan,
  Independent Director
• Kathy Ordonez,
  Independent Director
• Ruben Argueta,
  Director - Investor Relations
• Ann Rhoads,
  Director
• Karen Gibson,
  Senior Vice President, Information Systems and Business Transformation
• Dr. Chockalingam Palaniappan Ph.D.,
  Chief Innovation Officer
• Patrick E. Klein,
  Chief Admin. Officer
• Louise Brandy,
  Chief Information Officer
• Rhys de Callier,
  VP of Strategy & Portfolio Management
• Dr. Johannes Kehle,
  Pres of AnDiaTec Division
• Phillip S. Askim,
  VP, Associate Gen. Counsel & Sec.
• Michael S. Iskra,
  Chief Commercial Officer
• Joseph M. Busky CPA,
  Chief Financial Officer
• Karen C. Gibson,
  Sr. VP of Digital Health Bus. Unit
• Edward Keith Russell,
  Sr. VP of Bus. Devel.
• Michael Donald Abney Jr.,
  Sr. VP of North American Sales & Distribution
• Michelle A. Hodges,
  Sr. VP & Gen. Counsel
• Group Inc.Carlyle Holdings ...,
  
• Thomas D Brown,
  Director
• Rodney F Dammeyer,
  Director
• John Tamerius,
  Sr. VP - Clinical/Reg Affairs
• Patrick Klein,
  Chief Administrative Officer
• Louise Brandy,
  SVP, Chief Information Officer
• Tamara A. Ranalli,
  SVP, Molecular Bus. Unit
• Mark W Smits,
  SVP-Commercial Operations
• Mark Pulido,
  Director
• John Matthew Radak,
  Chief Financial Officer
• Timothy Todd Stenzel,
  Chief Science Officer
• Scot M Mc Leod,
  Sr. VP - Operations
• Caren L Mason,
  President and CEO
• Jack W Schuler,
  Director
• Thomas James Foley,
  Chief Technical Officer
• David R. Scholl,
  Senior Vice President
• Richard C Iii Tarbox,
  Sr. VP - Corporate Development
• Matthew T Heindel,
  Sr. VP - Global Sales & Mrktg
• Douglas S Harrington,
  Director
• Faye Wattleton,
  Director
• Mark Paiz,
  Senior Vice President
• Thomas A Glaze,
  Director
• Paul E Landers,
  Sr. V.P., CFO and Secretary
• S Wayne Kay,
  President & CEO
• William J. Ferenczy,
  SVP, Cardio/Metabolic Unit
• Michael S. Iskra,
  EVP & CCO
• Christopher M Smith,
  Director
• Joseph D Jr. Wilkins,
  
• Evelyn S Dilsaver,
  
• Joseph M Busky,
  Chief Financial Officer
• James Prutow,
  
• Michelle A. Hodges,
  SVP, General Counsel